Beyond the Weight-Loss Numbers: How New Obesity Drugs Work, How Safe They Are, and What Investors Are Betting On
Published by RichStorm.co
Key Takeaways
Obesity drugs are more useful to compare across four questions: effectiveness, health benefit, safety, and whether the result can be maintained.
The leading programs use different combinations of GLP-1, GIP, glucagon, and amylin, with formats ranging from a daily pill to monthly or less frequent injections.
For investors, a larger weight-loss number is only one source of value. Tolerability, convenience, outcomes beyond weight, access, and long-term use may matter just as much.
1. Why the percentage is only the beginning
Every few months, another obesity drug makes headlines for the amount of weight people lost while taking it. The first question is obvious: does it work? But that quickly leads to others. What does it feel like to take? Is losing weight the same as becoming healthier? What happens when treatment stops? And could someone realistically stay on it for years?
Those four questions, effectiveness, health benefit, safety, and sustainability, offer a more useful way to look at obesity drugs than ranking them by weight loss alone. They also explain why companies continue to invest in new medicines when effective ones are already available.
2. Four hormone signals, seven drugs
Most of today's leading obesity drugs work with the signals the body uses to regulate hunger, fullness, and energy use. Four signals matter here.
GLP-1 is the anchor. Acting on its receptor reduces appetite and slows gastric emptying, so a person feels full sooner and eats less. Semaglutide and orforglipron work through this pathway alone.
GIP is a second gut hormone, and the field has not settled on which direction to push it. Tirzepatide activates GIP alongside GLP-1. Amgen's MariTide activates GLP-1 while blocking GIP. Both have produced substantial weight loss in trials, which suggests the role of this receptor is not yet settled.
Glucagon works on a different side of the equation. Activating its receptor may increase energy expenditure and fat breakdown in the liver, rather than only suppressing intake. Retatrutide adds glucagon as a third target on top of GLP-1 and GIP, while Innovent's mazdutide pairs it with GLP-1. Mazdutide trials have also reported reductions in liver fat alongside weight loss.
Amylin is a separate satiety signal. CagriSema combines an amylin analogue with semaglutide.
The seven drugs below were chosen because each represents a distinct design route, not because they form a complete list of the market. Approval dates refer specifically to obesity or weight management, rather than an earlier approval for diabetes. For drugs still in development, dosing and side effects come from trials rather than an approved label.
Status checked as of September 17, 2026. Approval months refer to regulatory authorization, which is not the same as commercial launch.
The table shows why convenience is not a single claim. A daily pill avoids injections but must be remembered every day. A monthly injection requires fewer dosing days, but patients still need to tolerate its effects and continue treatment. How a drug is taken could make a difference. Whether it actually improves long-term use is a separate question.
3. Effectiveness: what can we compare?
Several of these medicines have produced substantial weight loss in trials. But comparing drugs requires more than lining up the largest percentage in each company's announcement.
The clearest example is a trial that directly compared semaglutide and tirzepatide. Among 751 adults with obesity and without diabetes, average weight change at 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide. CagriSema also produced substantial weight loss, but in a direct comparison with tirzepatide it reached 23.0% against 25.5% in the trial's primary efficacy analysis and did not meet its prespecified goal of showing it was no worse. That result says something important about the comparison tested. It does not settle every question about CagriSema's potential use.
Population matters as much as comparator. Mazdutide's GLORY-1 trial enrolled Chinese adults whose average starting weight was considerably lower than in most Western trials, and it demonstrated clinically meaningful weight loss against placebo in that population. Reading its headline number next to a Western trial result would not be a like-for-like comparison.
Results for retatrutide and MariTide come from separate studies with different participants and treatment periods. They can show promise, but they cannot establish how those drugs would perform against one another. For readers, the useful question is not which announcement has the biggest number, but who was studied and against what comparator.
4. Safety: more than a list of warnings
The side effects most likely to affect daily life are digestive ones. Nausea, vomiting, diarrhea, and constipation appear repeatedly across all seven programs, usually while doses are being increased. They may be manageable for many people and hard to tolerate for others. This matters especially for a treatment meant to be continued rather than taken briefly.
The table lists common effects, but it should not be read as a safety ranking. Discontinuation rates vary widely across these programs, and the differences reflect doses, populations, trial lengths, and reporting methods as much as the drugs themselves. Three of the seven also have no approved prescribing label yet, so their safety profiles are still being established.
Approved labels describe less common but potentially serious concerns. The US labels for semaglutide, tirzepatide, and orforglipron discuss pancreatitis and gallbladder problems. The tirzepatide label carries a boxed warning based on thyroid tumors observed in rodents and states that whether the finding applies to humans is unknown. Orforglipron carries a related warning framed as a class effect, while noting that the molecule itself did not produce tumors in rodent studies. These warnings matter when deciding who should take a drug and what to monitor. They do not mean every listed event is equally frequent or equally well established as drug-caused.
5. Does losing weight mean gaining health?
Body weight is one measure. It does not tell us by itself how much of the change came from fat rather than lean tissue, or whether a person is functioning better physically. Lean mass is a broad measurement and is not interchangeable with muscle strength.
Evidence for specific health outcomes is accumulating, but each result belongs to a defined population and endpoint. In SELECT, which enrolled 17,604 adults aged 45 and over with established cardiovascular disease and overweight or obesity but not diabetes, major cardiovascular events occurred in 6.5% of the semaglutide group versus 8.0% on placebo. In SUMMIT, tirzepatide reduced a composite of cardiovascular death or worsening heart failure in 731 patients with obesity and heart failure with preserved ejection fraction, a result driven mainly by fewer worsening heart failure events rather than a difference in cardiovascular death. Tirzepatide is also approved in the United States for moderate-to-severe obstructive sleep apnea in adults with obesity.
These are not interchangeable findings. Preventing heart attacks and strokes in secondary prevention, reducing heart failure events, and improving sleep apnea severity are different claims, each earned in a different group of patients. A drug that has one does not automatically have the others, and each requires its own long trial.
6. What happens after the trial ends?
A trial lasting a year does not mean the intended treatment lasts a year. For medicines used in long-term weight management, the central question is often how to maintain the benefit, rather than simply how to achieve it.
Follow-up studies of semaglutide and tirzepatide both found substantial regain after treatment stopped. One detail is worth noting: in the semaglutide extension, the structured lifestyle intervention ended along with the drug, so the regain reflects withdrawal of a whole package of support, rather than the medicine alone.
Those findings should not be automatically copied onto every newer drug, but the alternatives studied so far all involve continuing treatment in some form. ATTAIN-MAINTAIN examined switching to orforglipron after an injectable; among participants whose weight had already stabilized, the pill preserved substantially more of the earlier loss than placebo did. For MariTide, Amgen reported in January 2026 that participants in the second part of its Phase 2 study maintained weight loss with lower or less frequent dosing, including quarterly administration. Neither result tells us what happens when treatment stops altogether.
This is where convenience becomes more consequential. If maintaining a benefit requires ongoing care, the experience of taking a drug, its side effects, access, and cost all become part of its practical value.
7. What, specifically, are investors paying for?
Backing another obesity medicine usually means paying for one of three things, and the three do not carry equal evidence.
Better efficacy is the most testable. Head-to-head trials already exist, and they have produced both wins and misses. A treatment people can sustain may take the form of an oral option, a monthly injection, or a gentler dose-escalation schedule, although the evidence remains mostly indirect. Health benefit beyond weight is no longer a single drug’s territory, but it remains fragmented. SELECT, SUMMIT, and the sleep apnea approval cover different populations and endpoints, and a new candidate inherits none of them.
Pfizer's acquisition of Metsera shows how this gets priced. Pfizer paid $65.60 per share in cash, an enterprise value of approximately $7 billion, plus a contingent value right of up to $20.65 per share tied to three clinical and regulatory milestones. The assets included a GLP-1 drug developed for weekly and monthly injection and an amylin candidate. Pfizer bought a portfolio of possible ways to compete, while the milestone-linked structure acknowledges that the differentiation still has to be proven.
The commercial opportunity also depends on who is eligible for treatment and whether patients can obtain and continue it. A larger weight-loss result, by itself, cannot settle an investment case.
8. What to watch next
When another striking result appears, three questions put it in context. Was the drug compared directly with an existing option, and in which population? What is known about tolerability and maintaining the result? Has it shown a health benefit beyond weight loss, in which patients and against which endpoint?
A better obesity drug might produce greater weight loss. It might also make useful treatment easier to continue, or demonstrate a benefit that matters beyond the scale. Those are different forms of progress, and each needs its own evidence.
ABOUT THE AUTHOR
Ximeng Zheng
Ximeng Zheng is a biotechnology graduate student at the University of Pennsylvania with a background in scientific research and a strong interest in life sciences and healthcare innovation. Her interests center on clinical translation and commercialization, particularly how scientific evidence and market considerations inform investment, business development, and strategic decision-making. She is passionate about translating scientific advances into products and solutions that create real-world impact.
References
1. Innovent Biologics. Mazdutide development and GLP-1/glucagon receptor mechanism. 2025 J.P. Morgan Healthcare Conference presentation.
2. Ji L, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight. New England Journal of Medicine. 2025;392(22):2215-2225. doi:10.1056/NEJMoa2411528.
3. US Food and Drug Administration. FDA approves Wegovy for chronic weight management. June 2021.
4. Novo Nordisk China. Wegovy approval announcement in China. June 2024.
5. Pharmaceuticals and Medical Devices Agency. Review Reports: Drugs. Wegovy listed as approved in March 2023.
6. US Food and Drug Administration. Wegovy (semaglutide) US prescribing information. Revised June 2026.
7. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564.
8. US Food and Drug Administration. FDA approves Zepbound (tirzepatide) for chronic weight management. November 8, 2023.
9. China Pharmaceutical News. Mufengda weight-management indication approved in China. August 2024.
10. Pharmaceuticals and Medical Devices Agency. Review Reports: Drugs. Zepbound listed as approved in December 2024.
11. US Food and Drug Administration. Zepbound (tirzepatide) US prescribing information.
12. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48.
13. Yicai. China approves its first domestically developed dual-target GLP-1 weight-management drug. June 27, 2025.
14. US Food and Drug Administration. FDA approves Foundayo (orforglipron). April 2026.
15. Eli Lilly. FDA approves Lilly's Foundayo (orforglipron). April 1, 2026.
16. Reuters, republished by The Standard. China approval for Eli Lilly's GLP-1 pill could come as soon as 2026. June 24, 2026.
17. US Food and Drug Administration. Foundayo (orforglipron) US prescribing information. Revised July 2026.
18. Aronne LJ, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. 2026;32:2679-2687.
19. Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema for weight management. December 18, 2025.
20. Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2025;393:635-647. doi:10.1056/NEJMoa2502081.
21. Eli Lilly. Retatrutide Phase 3 TRIUMPH-1 trial results. May 21, 2026.
22. Amgen. Results from Amgen's Phase 2 obesity study of monthly MariTide presented at the ADA Scientific Sessions. June 2025.
23. Amgen. J.P. Morgan Healthcare Conference investor presentation: MariTide Phase 2 maintenance results. January 2026.
24. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394.
25. Novo Nordisk. REDEFINE 4 head-to-head CagriSema-tirzepatide trial results. February 23, 2026.
26. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563.
27. Packer M, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. New England Journal of Medicine. 2025;392:427-437. doi:10.1056/NEJMoa2410027.
28. US Food and Drug Administration. FDA approves Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. December 20, 2024.
29. Pfizer. Pfizer completes acquisition of Metsera. November 13, 2025.
